Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent.
Sci Rep
; 10(1): 12772, 2020 07 29.
Article
in En
| MEDLINE
| ID: mdl-32728172
Full text:
1
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
DNA
/
Endometrial Neoplasms
/
Cross-Linking Reagents
/
Folate Receptors, GPI-Anchored
/
Triple Negative Breast Neoplasms
/
Antineoplastic Agents
Language:
En
Journal:
Sci Rep
Year:
2020
Type:
Article
Affiliation country:
United States